Trials Sponsors Conditions Drugs Pricing

Conditions

Anorexia Cachexia Carcinoma, Non-Small-Cell Lung Weight Loss

Outcome Measures

Primary Outcomes (1)

Functional capacity (strength and endurance), body composition by DXA, inflammation, patient reported outcomes, anti-tumor response rate
25 weeks

Secondary Outcomes (1)

Adverse events, ECG, vital signs, clinical laboratory parameters and physical examination
25 weeks

Interventions

BetamarcDrug

2 tabs BID

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Newly diagnosed Stage IIIB or IV non-resectable NSCLC. Recurrent disease after resection for earlier stage disease is acceptable as long as patients are at least 6 months from surgery.
Treatment plan includes a platinum-based doublet chemotherapy.

Sponsors & Collaborators

Anaborex
Industrylead

Study Sites (6)

Queen Elizabeth Hospital

Hong Kong, China

Tuen Mun Hospital

Hong Kong, China

China Medical University Hospital

Taichung, Taiwan

Taichung Veterans General Hospital

Taichung, Taiwan

Cathay General Hospital

Taipei, Taiwan

Taipei Medical University Muncipal Wan Fang Hospital

Taipei, Taiwan

MeSH Terms

Conditions

AnorexiaCachexiaWeight LossCarcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsBody Weight ChangesBody WeightThinnessCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic Neoplasms

Study Officials

Yung-chuan Sung
Cathay General Hospital
PRINCIPAL INVESTIGATOR
Hsing-jin Eugene Liu
Taipei Medical University Muncipal Wan Fang Hospital
PRINCIPAL INVESTIGATOR
Te-chun Hsia
China Medical University Hospital
PRINCIPAL INVESTIGATOR
Gee-chen Chang
Taichung Veterans General Hospital
PRINCIPAL INVESTIGATOR

Study Design

Study Type: interventional
Phase: phase 2
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

September 23, 2007

First Posted

September 26, 2007

Study Start

October 2007

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

June 2008

Actual (reported)

Study Stopped

Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (6)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (6)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations